Health Self Monitoring Technologies Market

On 5 March 2024, the US Food and Drug Administration cleared Dexcom’s Stelo, the first continuous glucose monitor anyone aged 18 or over could buy without a prescription, opening a sensor that had been a diabetes prescription item to about 25 million Americans with type 2 diabetes who do not use insulin (a population whose worst outcome, kidney failure, is sized in the Dialysis Equipment Market report), and to anyone curious about how food moves their blood sugar. Abbott’s over-the-counter Lingo followed in June 2024. That shift, from devices a doctor orders to devices a consumer buys, is the story of health self-monitoring. Douglas Insights values the health self-monitoring technologies market at USD 14.9 billion in 2025 and forecasts USD 33.0 billion by 2035, a compound growth rate of 8.32%. The receipt is about 386 million self-monitoring devices and sensors sold to consumers in 2025 at an average price of USD 38.50. Units grow 6.4% a year as smart rings, connected blood pressure monitors and over-the-counter glucose sensors reach new buyers; price grows 1.8% a year as buyers trade up to connected, clinically validated devices and subscriptions. The report sits within Douglas Insights coverage of consumer goods and retail and follows the published Douglas Insights research methodology.

What are health self-monitoring technologies?

Health self-monitoring technologies are the devices and sensors that consumers buy to measure their own health at home or on the body, about 386 million units worth USD 14.9 billion in 2025. They include health wearables such as smart rings and fitness bands that track heart rate, sleep and blood oxygen; home blood pressure monitors; digital thermometers and pulse oximeters; smart scales that measure weight and body composition; blood glucose meters and over-the-counter continuous glucose sensors; and personal ECG and sleep-testing devices. The market counts devices and over-the-counter sensors at retail value, including the app subscriptions sold with them. General-purpose smartwatches, prescription-only continuous glucose monitors, glucose test strips, and hospital or clinician-operated monitoring equipment sit outside the boundary.

How did over-the-counter glucose sensors change health self-monitoring technologies?

Over-the-counter glucose sensors turned a prescription medical device into a consumer product, and Douglas Insights estimates they lifted glucose self-monitoring value from about USD 0.9 billion in 2023 to USD 1.34 billion in 2025. Dexcom’s release on the Stelo clearance set out the first target group: adults with type 2 diabetes who do not use insulin. The sensor sits on the back of the arm for up to 15 days and reports to a phone app, and it is sold online without insurance. Because each sensor is replaced every two weeks, a committed user buys about 26 a year, so the category behaves like a subscription. Douglas Insights threads the clearance through this report: it makes glucose sensing the fastest-growing segment, it pulls pharmacy and online retail deeper into health devices, and the pace at which regulators in Europe, Japan and India follow is one of the swings in the scenarios.

Why are consumers monitoring their own health?

Consumers are monitoring their own health because chronic conditions are common, doctors’ time is scarce and devices have become cheap and connected: the World Health Organization estimates about 1.3 billion adults aged 30 to 79 live with hypertension, and about half of them do not know it. A home blood pressure monitor costs USD 30 to USD 80 and gives more readings in a week than a clinic visit gives in a year. Guidelines in the United States and Europe now recommend home readings to confirm a diagnosis and track treatment, and insurers and employers increasingly reward self-tracking. Douglas Insights estimates about 42% of 2025 self-monitoring value was bought by people managing a diagnosed condition, 38% by wellness and fitness buyers, and 20% by older adults and caregivers.

What drives health self-monitoring technologies demand to 2035?

Four drivers carry health self-monitoring technologies unit growth of 6.4% a year, and health wearables are the largest. Smart rings and fitness bands have shifted from step counting to sleep, heart rhythm, temperature and blood oxygen tracking, and ring makers sell subscriptions on top of the hardware. Douglas Insights values health wearables at USD 6.54 billion in 2025, 44% of the market, growing 8.6% a year, and estimates smart ring shipments passed 5 million units in 2025, roughly three times the 2022 level. Rings suit sleep and temperature tracking better than wrist devices, and the entry of Samsung’s Galaxy Ring in July 2024 brought a phone ecosystem into a category Oura had largely built alone.

Over-the-counter glucose sensing is the second driver and the fastest-growing. Stelo and Lingo created a retail category in 2024, and weight-loss medicines have made millions more people curious about blood sugar. Douglas Insights values glucose meters and over-the-counter sensors at USD 1.34 billion in 2025, growing 15.5% a year, and models over-the-counter sensors passing 60% of that segment’s value by 2030.

Ageing populations and chronic disease are the third driver. People aged 65 and over will number about 1 billion worldwide by the early 2030s, and each of them is a likely buyer of a blood pressure monitor, thermometer, pulse oximeter or fall-alert wearable. Douglas Insights values home blood pressure monitors at USD 2.53 billion in 2025, growing 5.8% a year, with connected cuffs that send readings to a doctor’s app rising from about 35% of units in 2025 to 60% by 2035. In the United States, remote patient monitoring billing codes let doctors bill for reviewing home readings, which has turned the connected cuff into a device that clinics hand out as well as one patients buy.

Online and pharmacy retail are the fourth driver. Online channels carried about 46% of self-monitoring value in 2025, USD 6.84 billion, and pharmacies 31%, and both now run health-device shelves and subscription programmes. Douglas Insights estimates online share rises about 1 point a year, which also lifts average prices because connected models sell better online than on a shelf.

What could restrain health self-monitoring technologies sales?

Three restraints are built into the health self-monitoring technologies forecast, and accuracy and regulation are the first. Regulators separate cleared medical devices from wellness gadgets, and the US FDA warned in February 2024 against smartwatches and rings that claim to measure blood glucose without piercing the skin. Douglas Insights estimates that about 30% of devices sold in 2025 carried no medical clearance, and a tougher line on wellness claims would slow sales of the cheapest devices.

Engagement fall-off is the second restraint. Many buyers stop wearing a band or ring within a year, and Douglas Insights estimates about 35% of health wearables are abandoned within 12 months, which limits repeat purchase and subscription revenue.

Data privacy is the third restraint. Health data collected by consumer devices sits outside many medical privacy laws, and new state laws in the United States and the EU’s rules on health data are raising compliance costs. Douglas Insights removes about 0.3 points a year from unit growth for privacy and abandonment together.

Which health self-monitoring technologies segments carry the value?

Health wearables lead the health self-monitoring technologies market with 44% of 2025 value, while glucose meters and over-the-counter sensors are the fastest-growing segment at 15.5% a year. Every product holds its share for a different reason.

Health wearables are worth USD 6.54 billion in 2025. They lead because a ring or band is worn all day, sells at USD 30 to USD 450, and increasingly carries a monthly subscription.

Home blood pressure monitors are worth USD 2.53 billion in 2025. Clinical guidelines now ask patients to measure at home, so the cuff is the most common medical device in households with hypertension.

Thermometers and pulse oximeters are worth USD 2.23 billion in 2025. Almost every household owns a thermometer, and the pandemic put a pulse oximeter in tens of millions more, so growth is slowest at 4.4% a year.

Smart scales and body composition devices are worth USD 1.63 billion in 2025, growing 6.8% a year as weight-loss medicines and fitness apps drive regular weigh-ins.

Glucose meters and over-the-counter sensors are worth USD 1.34 billion in 2025 and form the fastest-growing segment at 15.5% a year, because over-the-counter sensors are bought every two weeks.

Personal ECG and sleep devices are worth USD 594.4 million in 2025, covering single-lead ECG monitors and home sleep testing, growing 9.5% a year.

How do technology, channel and buyer split health self-monitoring demand?

By technology, connected devices that sync to an app account for USD 9.51 billion (64%) of 2025 value and standalone devices for USD 5.35 billion (36%). By channel, online retail accounts for USD 6.84 billion (46%), pharmacies and drug stores for USD 4.61 billion (31%), and mass retail and electronics stores for USD 3.42 billion (23%). By end user, people managing a diagnosed condition buy USD 6.24 billion (42%), wellness and fitness buyers USD 5.65 billion (38%), and older adults and caregivers USD 2.97 billion (20%).

Which regions buy the most health self-monitoring technologies?

North America buys 34% of health self-monitoring technologies by value, USD 5.05 billion in 2025, while Asia Pacific grows fastest at 9.9% a year. North America leads because over-the-counter glucose sensors were cleared there first, smart ring brands launched there, and consumers pay for subscriptions. The region grows 7.3% a year.

Asia Pacific buys USD 4.90 billion and grows 9.9% a year, the fastest rate. China’s low-cost bands and scales, Japan’s large blood pressure monitor market and India’s growing middle class with high rates of diabetes and hypertension all add demand.

Europe buys USD 3.72 billion and grows 7.2%, with strong pharmacy channels and reimbursement for some connected monitors. Latin America buys USD 668.7 million and grows 8.9%. The Middle East is the wildcard at USD 297.2 million and 9.1% a year, where high diabetes rates in the Gulf meet high smartphone use. Africa buys USD 222.9 million and grows 8.6%.

Who are the leading health self-monitoring technologies suppliers?

Douglas Insights estimates that the three largest health self-monitoring technologies suppliers hold about 19% of 2025 value, led by Omron at about 7%, in a market split across wearables, medical devices and consumer electronics.

Advantage in health self-monitoring technologies rests on clinical credibility or on price and ecosystem. Omron wins on validated accuracy and pharmacy shelf space; Oura wins on ring design, sleep analytics and a subscription base; Xiaomi and Huawei win on low prices and phone ecosystems in Asia; Dexcom and Abbott bring medical-grade glucose sensing to retail. The winners increasingly combine a cleared device, an app that turns readings into advice, and a subscription.

How are health self-monitoring technologies priced?

Health self-monitoring technologies sold for an average of USD 38.50 per device in 2025, and Douglas Insights expects about USD 46 by 2035. Digital thermometers sell for USD 5 to USD 40, pulse oximeters for USD 15 to USD 60, blood pressure monitors for USD 30 to USD 120, smart scales for USD 25 to USD 150, fitness bands for USD 30 to USD 150 and smart rings for USD 250 to USD 450. Over-the-counter glucose sensors sell for about USD 50 to USD 100 per two-week sensor, or USD 90 to USD 100 a month on subscription. App subscriptions of USD 6 to USD 15 a month add recurring revenue on top of hardware.

Which rules apply to health self-monitoring technologies?

Health self-monitoring technologies are regulated by what they claim: devices that diagnose or measure for medical use, such as blood pressure monitors, glucose sensors and ECG devices, need FDA clearance in the United States or CE marking under the EU Medical Device Regulation, while wellness trackers do not. Blood pressure monitors are validated against the ISO 81060-2 accuracy standard, and glucose sensors against FDA performance criteria. Health data from consumer devices is covered by privacy and consumer protection rules rather than hospital privacy law in many markets. The Continuous Glucose Monitoring Sensor Manufacturing Market report covers how the sensors themselves are made.

How do subscriptions change health self-monitoring technologies economics?

Subscriptions turn health self-monitoring technologies from one-off gadgets into recurring revenue, and Douglas Insights estimates app and sensor subscriptions made up about 11% of 2025 market value, rising to about 20% by 2035. A smart ring buyer typically pays USD 6 a month for the full sleep and readiness analysis, an over-the-counter glucose user pays for a fresh sensor every 15 days, and connected scale and blood pressure apps sell coaching plans on top of free readings. Over five years, a subscribing ring owner spends about as much on the service as on the ring itself. That changes how makers compete: they price hardware close to cost to win the subscriber, measure success by retention rather than units, and invest in software that turns raw readings into advice. It also explains why the price leg rises 1.8% a year even though sensor hardware keeps getting cheaper.

How do weight-loss medicines affect health self-monitoring technologies?

Weight-loss medicines such as semaglutide and tirzepatide are pushing millions of new users toward health self-monitoring technologies, and Douglas Insights estimates they added about 0.5 points to 2025 unit growth in the United States through smart scales, glucose sensors and protein and activity tracking. People taking these medicines lose weight quickly, want to see body composition rather than weight alone, and are often told to watch blood sugar and muscle mass. Smart scale makers report rising sales of body-composition models, and glucose sensor brands market directly to this group. Douglas Insights models smart scales and over-the-counter glucose sensors gaining most from this trend, and treats a fall in the price of these medicines, which would widen their use, as an upside in the mass-adoption scenario.

How far could health self-monitoring technologies reach under each scenario?

The base scenario takes the health self-monitoring technologies market to USD 33.0 billion by 2035, with a range of USD 23.8 billion to USD 43.9 billion. The base case combines 6.4% unit growth with 1.8% price growth for 8.32% a year. The slower-adoption scenario assumes regulators tighten wellness claims, abandonment stays high and over-the-counter glucose sensors stay limited to the United States, setting the legs at 4.2% and 0.6% for USD 23.8 billion. The mass-adoption scenario assumes over-the-counter sensors spread worldwide and insurers pay for home monitoring, setting the legs at 8.4% and 2.8% for USD 43.9 billion. Each 1-point change in unit growth moves the 2035 figure by about USD 3.24 billion. Published forecasts from earlier years ran at 28% to 31% a year on a much wider boundary that included smartwatches and apps; the Douglas Insights 8.32% excludes general-purpose smartwatches and counts devices at retail value.

Douglas Exclusive: the self-monitoring adoption tracker

The self-monitoring adoption tracker follows, for 25 countries, household ownership of each device type, the share of devices that are connected and clinically cleared, subscription take-up, abandonment rates and the regulatory status of over-the-counter glucose sensors. It shows device makers where the next buyers are and shows pharmacy and online retailers which categories are moving from gadget to routine health tool. It links to the Hearing Aids Market report, where a similar over-the-counter shift began in October 2022, and to the Smart Home Market report for home-based health devices.

Methodology and receipts

The health self-monitoring technologies model is built bottom-up from devices. The headline receipt is 386 million devices multiplied by USD 38.50, giving USD 14.9 billion for 2025. Units are estimated for six product types across 25 countries from company disclosures, shipment trackers, pharmacy and online sales data and household ownership surveys, and prices are average retail prices by product and region. The forecast compounds 6.4% unit growth and 1.8% price growth from the 2025 base to about 718 million devices and USD 33.0 billion in 2035.

Sources

1. DexCom, Inc. Stelo by Dexcom first glucose biosensor cleared by FDA as over-the-counter (2024)
2. World Health Organization WHO Global Health Observatory: noncommunicable disease indicators (2026)
3. United Nations Statistics Division UN Comtrade: trade flows in medical and measuring instruments (2026)